Gamal Shiha

Gamal Shiha is an expert in Hepatology at Mansoura University (Egypt). As of October 2026, ScienceLeadR ranks Gamal Shiha in the top 1% of experts worldwide for Hepatitis, and in the top 1% of experts in Egypt for Liver Neoplasms and Carcinoma. Gamal Shiha has authored 237 publications, the most recent in 2026, and is an investigator in 4 clinical trials, 1 of them ongoing. SLR score: 893 (community average: 125). How the SLR is computed.

Hepatology

Subspecialties: Gastroenterology - Pharmacy - Infectiology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on October 30, 2026

Expert Rankings

Top experts on the MeSH terms this expert works on

Top Carcinoma key opinion leaders

Organizations

Career arc: 1983 - 2026

Source: PubMed

Faculty of Medicine - Mansoura University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 237

Citations

Citations: 13 638 1st author: 68 Last author: 40 Unique author: 3

Main journals

J Hepatol 41

Hepatol Int 30

Lancet Gastroenterol Hepatol 11

Liver Int 10

J Viral Hepat 9

Best Journals

J Hepatol 14

Lancet Gastroenterol Hepatol 6

Lancet Oncol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title	Journal	Year	Citations
Biomaterial-Based Regulation of Mesenchymal Stromal Cell Hepatic Differentiation for Liver Regeneration. PMID 42939012 — liver regeneration, cells, hepatocytes, polylactic acid-polyglycolic acid copolymer, phenotype, mesenchymal stem cells, biocompatible materials, liver, tissue engineering, stromal cells, extracellular matrix, transplantation	Bioengineering (Basel)	2026	0
Correction: The Asian Pacific Association of the Study of the Liver expert survey on artificial intelligence-assisted reporting of liver histopathology in metabolic dysfunction associated fatty liver disease. PMID 42637880 — liver diseases, intelligence, liver, artificial intelligence, fatty liver	Hepatol Int	2026	0
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study. PMID 42636832 — carcinoma, hepatocellular, progression-free survival, neoplasms, drug-related side effects and adverse reactions, therapeutics	Lancet Oncol Top journal	2026	0
Endoscopic ultrasound strain elastography in MASLD: Evaluation against transient elastography and non-invasive markers. PMID 42602103 — fibrosis, elasticity imaging techniques, liver, diagnosis, fatty liver	Hepatol Forum	2026	0
A global consensus on the critical care management of acute-on-chronic liver failure patients: the APASL ACLF Beijing Position Paper. PMID 42533257 — liver diseases, acute-on-chronic liver failure, multiple chronic conditions, critical care, liver, therapeutics, liver failure	Hepatol Int	2026	1

Clinical Studies 4

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 3

Phase 2/Phase 3 1

By status:

Completed 3

Active not recruiting 1

By type:

Interventional 4

By Monocentric/Multicentric:

monocentric 2

multicentric2to4 1

multicentric5to9 0

multicentricup10 1

Main Topics

Digestive System Diseases 4

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study	Phase	Status	Start
Evaluate Durvalumab and Tremelimumab Lenvatinib in Combination With TACE in Patients With Locoregional HCC NCT05301842 — injections, carcinoma, hepatocellular, neoplasms, hepatic artery, arteries, liver, liver neoplasms, carcinoma	Phase 3	Active not recruiting	2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS

Shopping Cart

System Maintenance Notice